Subcutaneous sarcoidosis: a case series from a single center.

Autor:	Cedirian S; Unit of Dermatology, IRCCS University Hospital of Bologna, Bologna, Italy.; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy., Comellini V; Unit of Respiratory and Critical Care Unit, IRCCS University Hospital of Bologna, Bologna, Italy., Chessa MA; Unit of Dermatology, IRCCS University Hospital of Bologna, Bologna, Italy.; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy., Ravaioli GM; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy., Misciali C; Unit of Dermatology, IRCCS University Hospital of Bologna, Bologna, Italy., Nava S; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.; Unit of Respiratory and Critical Care Unit, IRCCS University Hospital of Bologna, Bologna, Italy., LA Placa M; Unit of Dermatology, IRCCS University Hospital of Bologna, Bologna, Italy - michelangelo.laplaca@unibo.it.; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Jazyk:	angličtina
Zdroj:	Italian journal of dermatology and venereology [Ital J Dermatol Venerol] 2024 Jun; Vol. 159 (3), pp. 344-348.
DOI:	10.23736/S2784-8671.24.07711-9
Abstrakt:	Background: Sarcoidosis is a multisystemic granulomatous disease which not only affect the skin but can also involve the lymph nodes, eyes, and lungs. Subcutaneous sarcoidosis (SCS), is a rare form of sarcoidosis which is generally more prevalent in women in their 40s and 50s, characterized by subcutaneous, flesh-colored nodules, mostly localized on the limbs. A retrospective study to investigate clinical features and response to treatment in patients affected by SCS. Methods: All patients with systemic and/or cutaneous sarcoidosis visited in our clinic hospital between 2012 and 2022. Out of this group, clinical features, and management of SCS patients were analyzed. Results: Out of 102 patients with specific lesions of cutaneous sarcoidosis, with or without systemic involvement, 13 (13%) were diagnosed with SCS. Conclusions: Our study confirms that systemic involvement in SCS is the prevalent finding as expected. Moreover, SCS patients have a relatively good prognosis, and systemic treatment does not differ from first-line therapies for cutaneous sarcoidosis.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu